2013;28:
123-31.
205. Gillet JL, Guedes JM, Guex JJ, et al. Side-effects and complications
of foam sclerotherapy of the great and small saphenous veins: a
controlled multicentre prospective study including 1,025 patients.
Phlebology 2009;24:131-8.
206. Todd KL 3rd, Wright DI, Group V-I. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efﬁcacy and safety
of polidocanol endovenous microfoam 0.5% and 1.0% compared
with placebo for the treatment of saphenofemoral junction
incompetence. Phlebology 2014;29:608-18.

Journal of Vascular Surgery: Venous and Lymphatic Disorders

Gloviczki et al

63

Volume 12, Number 1
207. Todd KL 3rd, Wright DI. VANISH-2 Investigator Group. Durability of
treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). J Vasc Surg
Venous Lymphat Disord 2015;3(3):258-64.e1.
208. King JT, O’Byrne M, Vasquez M, Wright D, Group V-I. Treatment of
truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation
improves symptoms and appearance. Eur J Vasc Endovasc Surg
2015;50:784-93.
209. Lal BK, Mallick R, Wright D. Improvement in patient-reported outcomes of varicose veins following treatment with polidocanol
endovenous microfoam. Phlebology 2017;32:342-54.
210. Kim PS, Elias S, Gasparis A, Labropoulos N. Results of polidocanol
endovenous microfoam in clinical practice. J Vasc Surg